U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
Experts express enthusiasm after US health regulators approved the first new form of treatment for schizophrenia in decades.
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback